Trials / Recruiting
RecruitingNCT07289477
A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy
A Phase I/III Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Putamen Transplantation of NouvNeu001 Injection for Multiple System Atrophy
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- iRegene Therapeutics Co., Ltd. · Industry
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Multiple System Atrophy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Human Dopaminergic Progenitor Cells | Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain. |
Timeline
- Start date
- 2026-01-05
- Primary completion
- 2027-10-01
- Completion
- 2031-07-01
- First posted
- 2025-12-17
- Last updated
- 2026-04-14
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07289477. Inclusion in this directory is not an endorsement.